Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications
- PMID: 21055812
- DOI: 10.1016/j.ophtha.2010.08.038
Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications
Abstract
Purpose: To evaluate the effects of intervals between preoperative intravitreal injection of bevacizumab (IVB) and surgery on the components of removed diabetic fibrovascular proliferative membranes.
Design: Interventional, consecutive, prospective, comparative case series.
Participants: A total of 52 eyes of 49 patients with active diabetic fibrovascular proliferation with complications necessitating vitrectomy.
Methods: Participant eyes that had IVB were divided into 8 groups in which vitreoretinal surgery was performed at days 1, 3, 5, 7, 10, 15, 20, and 30 postinjection. A group of eyes with the same diagnosis and surgical intervention without IVB injection was used for comparison. In all eyes, proliferative membrane specimens obtained during vitrectomy were sent for histopathologic examination using hematoxylin-eosin stain, immunohistochemistry (CD34 and smooth muscle actin), and Masson's trichrome stain.
Main outcome measures: Comparative analysis of different components of the fibrovascular proliferation (CD34, smooth muscle actin, and collagen) among the study groups.
Results: Pan-endothelial marker CD34 expression levels starting from day 5 postinjection were significantly less than in the control group (P < 0.001), with minimum expression (1+) in all specimens removed at or after day 30 postinjection. Positive staining for smooth muscle actin was barely detected in the control eyes at day 1, and consistently intense at day 15 and beyond (P < 0.001). The expression level of trichrome staining was significantly high at day 10, compared with control eyes (P < 0.001), and continued to increase at subsequent surgical time points.
Conclusions: A profibrotic switch was observed in diabetic fibrovascular proliferation after IVB, and our results suggest that at approximately 10 days post-IVB the vascular component of proliferation is markedly reduced, whereas the contractile components (smooth muscle actin and collagen) are not yet abundant.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.Ophthalmology. 2009 May;116(5):927-38. doi: 10.1016/j.ophtha.2008.11.005. Epub 2009 Mar 9. Ophthalmology. 2009. PMID: 19269033
-
Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.Ophthalmology. 2009 May;116(5):921-6. doi: 10.1016/j.ophtha.2008.12.024. Ophthalmology. 2009. PMID: 19410951
-
Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.Ophthalmology. 2009 Oct;116(10):1943-8. doi: 10.1016/j.ophtha.2009.07.001. Epub 2009 Aug 21. Ophthalmology. 2009. PMID: 19699531 Clinical Trial.
-
Antiangiogenic drugs and advanced proliferative diabetic retinopathy.Arq Bras Oftalmol. 2011 Mar-Apr;74(2):143-6. doi: 10.1590/s0004-27492011000200017. Arq Bras Oftalmol. 2011. PMID: 21779675 Review.
-
Bevacizumab and diabetic vitrectomy.Int Ophthalmol Clin. 2014 Spring;54(2):111-26. doi: 10.1097/IIO.0000000000000013. Int Ophthalmol Clin. 2014. PMID: 24613888 Review. No abstract available.
Cited by
-
Change of Vascular Endothelial Growth Factor Levels following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy.J Ophthalmol. 2019 Oct 23;2019:6764932. doi: 10.1155/2019/6764932. eCollection 2019. J Ophthalmol. 2019. PMID: 31772768 Free PMC article.
-
Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.Int Ophthalmol. 2012 Apr;32(2):135-44. doi: 10.1007/s10792-012-9541-5. Epub 2012 Mar 27. Int Ophthalmol. 2012. PMID: 22450558
-
Serous retinal detachment after panretinal photocoagulation for proliferative diabetic retinopathy: a case report.J Med Case Rep. 2017 Sep 19;11(1):265. doi: 10.1186/s13256-017-1424-y. J Med Case Rep. 2017. PMID: 28923115 Free PMC article.
-
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.Br J Ophthalmol. 2012 Apr;96(4):587-90. doi: 10.1136/bjophthalmol-2011-301005. Epub 2012 Jan 29. Br J Ophthalmol. 2012. PMID: 22289291 Free PMC article.
-
Advances in Vitreoretinal Surgery.J Clin Med. 2022 Oct 30;11(21):6428. doi: 10.3390/jcm11216428. J Clin Med. 2022. PMID: 36362657 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous